To determine whether ACH has meaningful or significant anti-obesity or anti-diabetic effects, further research, including pharmacokinetic and pharmacological studies, in vivo experiments under physiological conditions, and potentially human clinical trials, is necessary. Here, FGFR3 is linked to obesity due to melanocortin 4 receptor deficiency.